Fairvalue-Calculator Fairvalue-Calculator
EN DE

CH Biotech R&D Co (6534) Fair Value & Analysis

Basic Materials · TW · Market cap 9.0B TWD

Price91.80 TWD
Fair Value92.02 TWD
Upside+0.2%
Quality95/100
Evidence: High Range 69.02 TWD – 115.03 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

CH Biotech R&D Co (6534) currently trades at 91.80 TWD, while our model-based Fair Value estimate is 92.02 TWD — implying the stock looks roughly 0.2% undervalued today. We read business quality at 95/100 (high quality), in the Basic Materials sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

CH Biotech R&D Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of agriculture chemicals in Taiwan, the United States, and internationally. It offers fertilizers, biostimulants, and plant growth regulators; and provides biotechnology services. The company was incorporated in 2013 and is headquartered in Nantou City, Taiwan.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is CH Biotech R&D Co (6534) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 92.02 TWD versus a price of 91.80 TWD — about +0% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 6534?
Our 21-model fair value for CH Biotech R&D Co is 92.02 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 91.80 TWD.
What is the quality score of 6534?
CH Biotech R&D Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.